[Heparins: from conventional to current approaches in the management of acute coronary ischemic syndromes].
The use of heparins in acute coronary syndromes has been established as antithrombine indication. In acute myocardial infarction, it is considered an adjunct therapy to reperfusion strategies. In patients with angina, this antithrombine therapy experts a synergic effect with antiplatelet drugs, which also have an antithrombine effect. This pharmacological information movides the possibility to use the traditional unfractioned heparin (UFH) and low molecular heparin (LMH), both are antithrombine drugs. The advantage of these low molecular heparins is their biodisponibility and easier use. Both types of heparins are relevant since there is valid information establishing that LMH is useful in acute coronary syndromes. Such as acute myocardial infarction (AMI), yielding better results than the UFH. Newer drugs, the pentasaccharides, have been reported recently, which. Newer drugs are small fractions of heparin, with antithrombine effects and which seem to be more powerful and effective offering better results. These drugs have been named pentasaccharides.